The FDA approved AbbVie’s next-generation dopamine therapy for Parkinson’s disease, tavapadon, now branded as Juvmo. The approval targets symptom relief with a formulation intended to reduce side effects versus earlier dopamine agonists. In oncology, Merck’s Welireg (tivozanib/other—based on the article) gained FDA clearance for a broader population of renal cell carcinoma patients when used in combination with Eisai’s Lenvima. The label expansion targets an expanded group of advanced renal cell carcinoma patients with a clear-cell component, per the filing summary. Together, the two approvals underscore regulators’ continued willingness to broaden neurology and targeted-oncology regimens—often by focusing on real-world tolerability and combination utility rather than single-agent efficacy alone.